The Value of Follow-Up Liver Stiffness Changes Measured by Virtual Touch Quantification Elastography for Predicting Recurrence of Gastroesophageal Varices after Endoscopic Injection Sclerotherapy on Cirrhotic Patients
Table 1
Baseline clinical characteristics of patients in the nonrecurrence and recurrence groups.
Characteristic
Training cohort ()
Validation cohort ()
a
Nonrecurrence ()
Recurrence ()
Nonrecurrence ()
Recurrence ()
Age (years)
0.436
0.111
0.635
Gender, no. (%)
0.510
0.217
0.626
Female
24 (48.0)
19 (41.0)
8 (33.33)
8 (53.33)
Male
26 (52.0)
27 (59.0)
16 (66.67)
8 (53.33)
BMI
0.403
0.268
0.392
Etiology
0.621
0.075
0.903
HBsAg
20 (40.0)
23 (50.0)
12 (50.00)
0 (0.00)
Alcoholic
11 (22.0)
9 (20.1)
8 (33.33)
2 (13.33)
Autoimmune
3 (6.0)
4 (8.7)
0 (0.00)
3 (20.00)
Unknown
16 (32.0)
10 (21.2)
0 (0.00)
4 (26.67)
Child-Pugh
0.598
0.268
0.756
A
30 (60.0)
30 (65.0)
17 (70.83)
8 (53.33)
B
20 (40.0)
16 (35.0)
7 (29.17)
7 (46.67)
MELD
8.00 (7.00-9.00)
8.00 (7.00-9.00)
0.385
8.00 (7.00-9.00)
8.00 (7.00-9.00)
0.953
0.634
Sarin type
0.117
0.918
0.948
GEV1
27 (61.1)
32 (36.8)
14 (58.33)
9 (60.00)
GEV2
23 (38.9)
14 (63.2)
10 (41.67)
6 (40.00)
Severity of GEV
0.287
0.686
0.676
Light
0 (0.0)
0 (0.0)
1 (4.17)
0 (0.00)
Medium
5 (10.0)
2 (4.0)
4 (16.67)
2 (13.33)
Severe
45 (90.0)
44 (96.0)
19 (79.17)
13 (86.67)
Red sigh
0.509
0.528
0.376
Negative
1 (2.0)
2 (4.0)
3 (12.50)
3 (20.00)
Positive
49 (98.0)
44 (96.0)
21 (87.50)
12 (80.00)
Portal vein thrombosis
0.474
0.784
0.860
Negative
36 (72.0)
30 (65.0)
17 (70.83)
10 (66.67)
Positive
14 (28.0)
16 (35.0)
7 (29.17)
5 (33.33)
Ascites
0.08
0.440
0.716
Negative
19 (38.0)
10 (21.7)
11 (45.83)
5 (33.33)
Positive
31 (62.0)
36 (78.3)
13 (54.17)
10 (66.67)
TB (μmol/L)
14.68 (11.15-17.84)
15.71 (13.34-21.39)
0.217
14.91 (10.61-18.95)
12.36 (10.79-14.88)
0.953
0.741
ALT (IU/mL)
0.427
0.306
0.429
AST (IU/mL)
0.404
0.131
0.178
ALP (IU/mL)
94.00 (72.75-116.25)
97.00 (79.00-133.00)
0.402
99.50 (80.00-144.75)
95.00 (75.00-108.00)
0.098
0.933
ALB
34.25 (30.65-36.90)
35.75 (33.15-39.63)
0.137
34.60 (31.40-35.10)
35.10 (32.00-39.10)
0.422
0.452
GGT (IU/mL)
29.50 (20.75-42.75)
34.00 (25.00-49.00)
0.128
30.00 (21.00-48.25)
32.00 (25.00-43.00)
0.464
0.895
Creatinine (IU/mL)
0.245
0.956
0.281
PLT (×103/μL)
68.50 (53.50-135.50)
82.00 (48.00-142.00)
0.704
68.50 (46.50-89.00)
74.00 (41.00-140.00)
0.585
0.487
INR
0.857
0.975
0.865
Post beta-blockers
0.670
0.603
0.317
Not received
25 (50.0)
25 (54.3)
14 (58.3)
10 (66.7)
Received
25 (50.0)
21 (45.7)
10 (41.7)
5 (33.3)
Data were shown as the deviation (SD) for normal distribution or the median and interquartile range (IQR) with nonnormal distribution. BMI: body mass index; TB: serum total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: glutamyl transpeptidase; INR: international normalized ratio; ALB: albumin; PLT: blood platelet; INR: international normalized ratio. aComparison between training dataset and validation dataset.
